Is there transparency in the pricing of medicines in the South African private sector?

V Bangalee; F Suleman

doi:10.7196/SAMJ.2018.v108i2.12815

In Practice

Is there transparency in the pricing of medicines in the South African private sector?

V Bangalee, F Suleman

Abstract

Recent investigations by the Competition Commission of South Africa (SA) of suspected excessive pricing of cancer medicines in SA by three global pharmaceutical companies have once again drawn attention to increasing medicine pricing transparency and warrant further public debate.

Authors' affiliations

V Bangalee, Discipline of Pharmaceutical Sciences, School of Health Sciences, Westville Campus, University of KwaZulu-Natal, Durban, South Africa

F Suleman, Discipline of Pharmaceutical Sciences, School of Health Sciences, Westville Campus, University of KwaZulu-Natal, Durban; and Prince Claus Chair of Development and Equity for the theme Affordable (Bio)Therapeutics for Public Health (September 2016 - September 2018), Faculty of Sciences, Utrecht University, Utrecht, The Netherlands